{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-139057","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.550261+00:00","generated_at":"2026-06-15T09:43:51.458412+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TScan enters $30M upfront collaboration with Amgen to identify Crohn's disease T-cell targets","bullets":["TScan receives $30M upfront; eligible for over $500M in development and commercial milestone payments.","Amgen gains exclusive global rights to develop and commercialize therapeutics from discovered targets.","Amgen holds an option to expand the collaboration to include ulcerative colitis under predefined terms.","TScan also earns tiered single-digit royalties on net sales from any products developed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-139057","json":"https://secwatch.observer/filing/0001193125-23-139057.json","markdown":"https://secwatch.observer/filing/0001193125-23-139057.md","text":"https://secwatch.observer/filing/0001193125-23-139057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523139057/0001193125-23-139057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523139057/d420303d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:43:51.458412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5fa8dfd234f2625bb8338bb9e42a2c875419257c","claim":"TScan Therapeutics, Inc. entered into Agreement with Amgen Inc. valued at $30 million (effective 2023-05-08).","evidence_excerpt":"On May 8, 2023, TScan Therapeutics, Inc. (“ TScan ” or the “ Company ”), entered into a Collaboration Agreement (the “ Agreement ”) with Amgen Inc. (“ Amgen ”) to identify antigens recognized by T cells in patients with Crohn’s disease utilizing the Company’s proprietary target discovery platform, TargetScan (“ TargetScan ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523139057/0001193125-23-139057-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Amgen Inc."},{"label":"Value","value":"$30 million"},{"label":"Effective","value":"2023-05-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}